Douglas Packer (Mayo Clinic, Rochester, USA) shares with Cardiac Rhythm News information on the design and rationale of the CABANA (Catheter ablation versus antiarrhythmic drug therapy for atrial fibrillation) trial, at the AF Symposium in Orlando, USA (8-11 January 2014).
According to Packer, who is the principal investigator of the trial, CABANA is a much larger study than previous studies comparing catheter ablation and antiarrhythmic drug therapy for atrial fibrillation. He said, “CABANA is not just looking at patients with paroxysmal atrial fibrillation, or just at young patients. It is looking at older patients who have an underlined disease, who have persistent and chronic atrial fibrillation. We are also looking at cost and quality of life.”
The CABANA trial is expecting to enrol 2,200 patients by the end of 2014 or beginning of 2015. Packer reported that up to now there are around 1,400 patients enrolled.